The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

• Published in: Alzheimer's research & therapy Vol. 10; no. 1; pp. 64 - 9
• Main Authors: Bos, Isabelle, Vos, Stephanie, Vandenberghe, Rik, Scheltens, Philip, Engelborghs, Sebastiaan, Frisoni, Giovanni, Molinuevo, José Luis, Wallin, Anders, Lleó, Alberto, Popp, Julius, Martinez-Lage, Pablo, Baird, Alison, Dobson, Richard, Legido-Quigley, Cristina, Sleegers, Kristel, Van Broeckhoven, Christine, Bertram, Lars, ten Kate, Mara, Barkhof, Frederik, Zetterberg, Henrik, Lovestone, Simon, Streffer, Johannes, Visser, Pieter Jelle
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.07.2018; BioMed Central; BMC
• Subjects: 1984; 1992; Aged; Aged, 80 and over; Alzheimer Disease - blood; Alzheimer Disease - diagnosis; Alzheimer's disease; alzheimers-disease; Amyloid beta-Peptides - blood; atrophy; Biological markers; Biomarkers; Biomarkers - blood; Biomedical Research - methods; blood-based; Care and treatment; Cerebrospinal fluid; cerebrospinal-fluid biomarkers; Chitinase-3-Like Protein 1 - blood; Cognitive ability; Cognitive Dysfunction; Cohort Studies; csf biomarkers; Dementia; Deoxyribonucleic acid; Diagnosis; DNA; DNA methylation; Female; Genetic testing; Genomics; Health aspects; heltens p; Humans; Initiatives; journal of neurology neurosurgery and psychiatry; khann g; Knowledge management; Magnetic Resonance Imaging; Male; Medical imaging; Metabolomics; Middle Aged; mild cognitive impairment; mri; Multimodal; Neurofilament Proteins - blood; Neurogranin - blood; neurology; Neuropsychological Tests; Neurosciences; Neurosciences & Neurology; Neurovetenskaper; NMR; Nuclear magnetic resonance; p939; p967; Pathology; Plasma; Proteomics; Psychiatric Status Rating Scales; Research Design; Research proposals; v34; v55; Metabolomics; Plasma; Alzheimer’s disease; Magnetic resonance imaging; Multimodal; DNA; Genomics; Proteomics; Biomarkers; Cerebrospinal fluid

There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer's disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD)...